Nasal spray shows promise against deadly brain cancer

NCT ID NCT02704858

Ongoing Disease control Sponsor: Neonc Technologies, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This study tests a nasal spray drug called NEO100 (perillyl alcohol) in people with aggressive brain tumors (grade III or IV gliomas) that have come back or worsened. The trial has two phases: first to find the safest dose, then to see if it helps patients live longer. About 49 participants will take the drug four times daily in 28-day cycles.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Perillyl alcohol (NEO100)
What this could lead to: If successful, this could offer a new treatment option for people with aggressive brain tumors that have returned or worsened.
What could go wrong: This is an early-phase trial with only 49 participants, so results may not apply to all patients. The drug is self-administered and may cause side effects or fail to improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anaplastic astrocytoma glioblastoma glioma susceptibility 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA MULTIFORME

Contacts and locations

Locations

Atlantic Health (Overlook Medical Center)

Summit, New Jersey, 07901, United States
Baylor Scott & White Health

Dallas, Texas, 75061, United States
Cleveland Clinic

Cleveland, Ohio, 44333, United States
Georgia Cancer Center (Augusta University)

Augusta, Georgia, 30912, United States
Northwell Health

New York, New York, 10016, United States
Ochsner Health

New Orleans, Louisiana, 70121, United States
Saint John Cancer Institute

Santa Monica, California, 90404, United States
Sutter Health Research Institute

San Francisco, California, 94110, United States
University of Southern California

Los Angeles, California, 90033, United States
University of Texas Southwestern Medical Center

Dallas, Texas, 75235, United States
Wake Forest University Health Sciences

Winston-Salem, North Carolina, 27157, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.